AmacaThera and Pacira BioSciences Sign $230 Million Licensing Deal for Long-Acting Anesthetic

November 04, 2025
AmacaThera has entered into an exclusive global licensing agreement with Pacira BioSciences worth up to $230 million to develop AMT-143, a long-acting non-opioid anesthetic for post-operative pain. Pacira will fund clinical development, manufacturing, and commercialization, with Phase 2 trials expected to start in 2026.

In a press release, AmacaThera announced an exclusive global licensing agreement with Pacira BioSciences valued at up to $230 million for AMT-143, AmacaThera’s long-acting non-opioid anesthetic designed for post-operative pain management.

AmacaThera will receive $5 million upfront and up to $225 million in potential milestone payments. AMT-143 leverages AmacaThera’s tunable hydrogel platform, which enables sustained local release of ropivacaine to provide extended pain relief.

Under the agreement, Pacira will fund the clinical development, manufacturing, and commercialization of AMT-143. Both companies plan to initiate a Phase 2 clinical trial in 2026, with AmacaThera leading select studies before Pacira assumes full responsibility for later-stage development and commercialization.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

11/04
Dr. Aaron Cohen-Gadol Launches ATLAS GPT for 35 Medical Specialties
11/04
Subtle Medical Brings AI MRI Enhancement Software to UK Market
11/04
SOPHiA GENETICS Raises 2025 Revenue Guidance After 23% Q3 Growth
11/04
Recor Medical Reports 19.6 mmHg Blood Pressure Reduction with Paradise System in Six Months
11/04
EY and KLAS Research Survey Finds Cybersecurity Now Core to Healthcare Strategy

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

AI’s Time-to-Market Quagmire: Why Enterprises Struggle to Scale AI Innovation

ModelOp

The 2025 AI Governance Benchmark Report by ModelOp provides insights from 100 senior AI and data leaders across various industries, highlighting the challenges enterprises face in scaling AI initiatives. The report emphasizes the importance of AI governance and automation in overcoming fragmented systems and inconsistent practices, showcasing how early adoption correlates with faster deployment and stronger ROI.

Read more

You May Also Like